Fluocortolone caproate

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Fluocortolone caproate is a corticosteroid indicated in the treatment of hemorrhoids, anal fissures, and corticosteroid-responsive dermatoses.

Generic Name
Fluocortolone caproate
DrugBank Accession Number
DB15821
Background

Not Available

Type
Small Molecule
Groups
Experimental
Structure
Weight
Average: 474.613
Monoisotopic: 474.278152519
Chemical Formula
C28H39FO5
Synonyms
  • Fluocortolone 21-caproate
  • Fluocortolone 21-hexanoate
  • Fluocortolone caproate
  • Fluocortolone hexanoate
External IDs
  • SH 770
  • SH-770

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Used in combination to treatAnal fissuresCombination Product in combination with: Fluocortolone pivalate (DB15777), Cinchocaine (DB00527)•••••••••••••••••••••••••• •••••••••••
Used in combination to treatHemorrhoidsCombination Product in combination with: Cinchocaine (DB00527), Fluocortolone pivalate (DB15777)•••••••••••••••••••••••••• •••••••••••
Used in combination to treatProctitisCombination Product in combination with: Fluocortolone pivalate (DB15777), Cinchocaine (DB00527)•••••••••••••••••••••••••• •••••••••••
Used in combination to treatCorticosteroid-responsive dermatosisCombination Product in combination with: Fluocortolone pivalate (DB15777)•••••••••••••••••• ••••••••
Used in combination to treatCorticosteroid-responsive dermatosisCombination Product in combination with: Fluocortolone pivalate (DB15777)•••••••••••••••••• ••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcarboseThe risk or severity of hyperglycemia can be increased when Fluocortolone caproate is combined with Acarbose.
AceclofenacThe risk or severity of gastrointestinal irritation can be increased when Fluocortolone caproate is combined with Aceclofenac.
AcemetacinThe risk or severity of gastrointestinal irritation can be increased when Fluocortolone caproate is combined with Acemetacin.
AcenocoumarolFluocortolone caproate may increase the anticoagulant activities of Acenocoumarol.
AcetohexamideThe risk or severity of hyperglycemia can be increased when Fluocortolone caproate is combined with Acetohexamide.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
International/Other Brands
Ficoid / Ultralanum
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
ULTRALAN DERMATOLOGICOFluocortolone caproate (0.25 %) + Fluocortolone pivalate (0.25 %)OintmentTopicalKaro Pharma Ab2014-07-082023-03-05Italy flag
ULTRALAN DERMATOLOGICOFluocortolone caproate (0.25 %) + Fluocortolone pivalate (0.25 %)CreamTopicalKaro Pharma Ab2014-07-08Not applicableItaly flag
ULTRALAN DERMATOLOGICOFluocortolone caproate (0.25 %) + Fluocortolone pivalate (0.25 %)OintmentTopicalKaro Pharma Ab2014-07-082020-09-25Italy flag
ULTRALAN DERMATOLOGICOFluocortolone caproate (0.25 %) + Fluocortolone pivalate (0.25 %)EmulsionTopicalKaro Pharma Ab2014-07-082020-09-25Italy flag
ULTRALAN DERMATOLOGICOFluocortolone caproate (0.25 %) + Fluocortolone pivalate (0.25 %)CreamTopicalKaro Pharma Ab2014-07-082021-08-11Italy flag

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
90893P8662
CAS number
303-40-2
InChI Key
WHZRCUIISKRTJL-YTZKRAOUSA-N
InChI
InChI=1S/C28H39FO5/c1-5-6-7-8-24(33)34-15-23(32)25-16(2)11-19-18-13-21(29)20-12-17(30)9-10-27(20,3)26(18)22(31)14-28(19,25)4/h9-10,12,16,18-19,21-22,25-26,31H,5-8,11,13-15H2,1-4H3/t16-,18+,19+,21+,22+,25-,26-,27+,28+/m1/s1
IUPAC Name
2-[(1S,2R,3aS,3bS,5S,9aR,9bS,10S,11aS)-5-fluoro-10-hydroxy-2,9a,11a-trimethyl-7-oxo-1H,2H,3H,3aH,3bH,4H,5H,7H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-yl]-2-oxoethyl hexanoate
SMILES
[H][C@@]12C[C@@H](C)[C@H](C(=O)COC(=O)CCCCC)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C

References

General References
  1. AIFA: Ultralan (Fluocortolone) Topical Cream [Link]
  2. TITCK Product Information: ULTRAPROCT (cinchocaine, fluocortolone pivalate, and fluocortolone caproate) rectal [Link]
ChemSpider
16735815
RxNav
4464
ChEMBL
CHEMBL2107415
ZINC
ZINC000004213356

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
CreamTopical
EmulsionTopical
LotionTopical
OintmentTopical
OintmentRectal
SuppositoryRectal
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0017 mg/mLALOGPS
logP3.67ALOGPS
logP4.44Chemaxon
logS-5.4ALOGPS
pKa (Strongest Acidic)15.15Chemaxon
pKa (Strongest Basic)-0.23Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count4Chemaxon
Hydrogen Donor Count1Chemaxon
Polar Surface Area80.67 Å2Chemaxon
Rotatable Bond Count8Chemaxon
Refractivity129.05 m3·mol-1Chemaxon
Polarizability52.93 Å3Chemaxon
Number of Rings4Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleYesChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0a6r-3009500000-3ba44af03b6cff4a342f
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-00r2-9304400000-bf850a3c48d0361840ea
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-002b-9007100000-f3cbb0be977d3d2e4fac
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0a6r-3009400000-38d269795c540cfdb713
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0a6u-9000000000-570e6b2fac75da65f585
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-00o0-9225000000-0b126925daf8858c4f50
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
Not Available

Drug created at September 09, 2020 20:13 / Updated at May 14, 2021 01:08